BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK signaling cascade, a signal transduction pathway that transmits mitogenic ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

BRAF gene fusions are much more common than BRAF ... it has two other assets in early development that target the BRAF-MAPK signalling pathway, including IPN01194 that started phase 1 earlier ...

Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant ...

One of the standard treatment options for melanoma over the last ten years has been to simultaneously target both BRAF mutations and MEK. These two genes are part of the MAPK signalling pathway ...

The trial, targeting advanced cancers with MAPK pathway mutations ... or in those who have not responded to BRAF/MEK inhibition. Pasithea plans to present updated PK and PD data during the ...

BRAF, and CRAF, potentially creating a more complete and durable anti-tumor response through maximal RAS/MAPK pathway inhibition. In contrast to currently available MEK-only inhibitors ...

Student feedback shows these programmes are career-enhancing. Demonstration of how BRAF and, more generally MAPK signalling, contribute to pituitary development, a key advance stemming from genetic ...